Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | 1 | Y | 1 TGR-1202 + Obinutuzumab | 150 | 18 | 10 | 5 | 1 | 0 | 0 | 01/23/2018 | 277 | 98 |
| 2 Lenalidomide + Obinutuzumab | 16 | 8 | 3 | 2 | 1 | 1 | ||||||||
| 3 CHOP + Obinutuzumab | 8 | 2 | 1 | 1 | 0 | 0 | ||||||||
| 4 Bendamustine + Obinutuzumab | 6 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 48 | 20 | 9 | 4 | 1 | 1 | |||||||||
| S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD | 1 | Y | 1 Nivolumab + AVD | 987 | 75 | 75 | 56 | 30 | 9 | 1 | 08/29/2019 | 285 | 131 | |
| 2 Brentuximab Vedotin + AVD | 74 | 74 | 57 | 28 | 9 | 2 | ||||||||
| 149 | 149 | 113 | 58 | 18 | 3 | |||||||||
| Yes | A051301-ABC DLBCL, Auto HCT and Ibrutinib/Placebo | 0 | E | Total Registrations | 58 | 3 | 2 | 1 | 0 | 0 | 10/12/2016 | 178 | 70 | |
| 58 | 3 | 2 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 8 | 2 | 1 | 1 | 1 | 0 | 10/12/2016 | |||||
| 8 | 2 | 1 | 1 | 1 | 0 | |||||||||
| E4412-HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | 1 | E | Total Registrations | 8 | 4 | 2 | 1 | 0 | 0 | 04/17/2019 | 133 | 56 | ||
| 8 | 4 | 2 | 1 | 0 | 0 | |||||||||
| EA4151-Lymph, AHCT +/-Ritux, MRD Neg | 0 | E | Total Registrations | 55 | 27 | 13 | 4 | 2 | 0 | 04/03/2018 | 169 | 75 | ||
| 55 | 27 | 13 | 4 | 2 | 0 | |||||||||
| 1 | E | Total Registrations | 42 | 21 | 12 | 5 | 0 | 0 | 04/03/2018 | |||||
| 42 | 21 | 12 | 5 | 0 | 0 | |||||||||
| EA4181-MCL, Randomization BR/CR v BR/CR-A v BR-A | 1 | E | Total Registrations | 8 | 8 | 7 | 4 | 1 | 0 | 12/13/2019 | 90 | 33 | ||
| 8 | 8 | 7 | 4 | 1 | 0 | |||||||||
| No | A051701-LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | 1 | E | Total Registrations | 19 | 19 | 17 | 9 | 4 | 1 | 01/02/2020 | 212 | 90 | |
| 19 | 19 | 17 | 9 | 4 | 1 | |||||||||